Short Communication

Double Oral Administration of Emtricitabine/Tenofovir Prior to Virus Exposure Protects against Highly Pathogenic Simian/Human Immunodeficiency Virus Infection in Macaques

Tadashi Nakasone^{1*}, Tsutomu Murakami¹, and Naoki Yamamoto^{1,2}

¹*AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; and*

²*Department of Microbiology, National University of Singapore, Singapore 117597, Singapore*

(Received March 27, 2012. Accepted June 4, 2012)

SUMMARY: In the absence of any effective vaccine against human immunodeficiency virus (HIV), current anti-retroviral drugs may be suitable for pre-exposure prophylaxis (PrEP). Previous large clinical trials showed that PrEP reduced HIV infection in high-risk populations. Emtricitabine/tenofovir (FTC/TDF) may be a suitable agent for PrEP. FTC/TDF PrEP efficacy was evaluated using a highly pathogenic simian/human immunodeficiency virus (SHIV) in a non-human primate model of AIDS, the SHIV-KS661c/cynomolgus monkey model. Double oral administration of FTC/TDF (20/30 mg/kg), at 24 h and a few minutes prior to exposure, completely protected 2/3 monkeys from infection. Interestingly, a single oral administration 2 weeks before viral exposure moderately rescued CD4 cells, although the data did not reach statistical significance. These results are consistent with previous primate studies and with recent clinical data.

UNAIDS estimated that 33.3 million people were living with human immunodeficiency virus (HIV) at the end of 2009 (1). The development of an effective vaccine against HIV is urgently needed and is critical to stop the spread of HIV. Although the STEP study was a disappointment in 2007 (2–4), the ALVAC/AIDSVAX study conducted in Thailand was more encouraging (5); however, efficacy remains uncertain and it may well be several more years before an effective HIV vaccine is available in the clinic.

Fortunately, the number of new HIV infections has decreased each year since 1996, and HIV prevalence among young people has also declined in many countries (1). Many interventions, such as safe sex education, condom use, risk reduction through the use of anti-retroviral drugs, and male circumcision, have contributed to this decline. Pre-exposure prophylaxis (PrEP) with anti-retroviral drugs is also considered a possible option to prevent infection with HIV (6–9). Recent preclinical and clinical studies demonstrated that PrEP significantly reduces virus infection and suggested that emtricitabine/tenofovir (FTC/TDF) may be a suitable pre-exposure prophylactic agent (10–16).

Many FTC/TDF preclinical studies have been conducted in the context of PrEP in simian immunodeficiency virus (SIV)/monkey models and pathogenic CCR5-tropic simian/human immunodeficiency virus (SHIV)/monkey models (10–13). The present study evaluates the PrEP efficacy of FTC/TDF in a highly pathogenic and “CXCR4-tropic” SHIV/non-human

primate (NHP) model of AIDS.

The monkey experiments were conducted at the Tsukuba Primate Research Center, National Institute of Biomedical Innovation (NIBIO), Japan, in accordance with the requirements specifically stated in the laboratory biosafety manual of the World Health Organization. The animals were housed in accordance with the Guidelines for Animal Experimentation of the Japanese Association for Laboratory Animal Science (1987) under the Japanese Law Concerning the Protection and Management of Animals and were maintained in accordance with the guidelines set by the Institutional Animal Care and Use Committee (IACUC) of NIBIO, Japan. The IACUC of NIBIO and that of the National Institute of Infectious Diseases (NIID) of Japan approved the study. Both guidelines are in accordance with the recommendations of the Weatherall report “The use of non-human primates in research”. The use of SHIV was also approved by the Institutional Advisory Committees for the Biosafety of Living Modified Organisms of NIBIO and NIID with the approval (Dai17-17) of the Japanese Minister of Education, Culture, Sports, Science and Technology (2005). Ethical standards incorporated into these guidelines and into our routine laboratory procedures included a maximum reduction in the number of animals, a psychological enrichment program, frequent contact with other animals (visual, auditory, and olfactory), and regular veterinary supervision and care.

Truvada® tablets (FTC/TDF) were purchased from Japan Tobacco Inc. (Tokyo, Japan). The tablets were ground and suspended in water immediately before use. Both FTC and TDF are nucleoside analogue reverse transcriptase inhibitors.

SHIV-KS661c, molecularly cloned from SHIV-C2/1, was used. The SHIV-C2/1 stock comprised plasma obtained by serum passages of p-SHIV (derived from

*Corresponding author: Mailing address: AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. Tel: +81-3-5285-1111 ext. 2737, Fax: +81-3-5285-1150, E-mail: nakabone@nih.go.jp

Fig. 1. Study design. Nine cynomolgus monkeys were divided into 3 groups (G1–G3), each comprising 3 animals. G1, double oral administration of FTC/TDF (20/30 mg/kg) 24 h and a few minutes before viral challenge; G2, single oral administration of FTC/TDF (20/30 mg/kg) 2 weeks before viral challenge; G3, naïve control monkeys. The drug was administered intragastrically via a nasal feeding tube under anesthesia. All animals were challenged intra-rectally with 10 times the AID_{50} of SHIV-KS661c and were monitored for more than 12 weeks.

SHIV-89.6) in cynomolgus monkeys (17–19). SHIV-KS661c was propagated in CEMx174 cells and was confirmed to be genetically identical to the major sequences of the parent virus. SHIV-KS661c can infect cynomolgus monkeys both intravenously and intra-rectally. The virus induces precipitous viremia and drastic CD4 cell depletion within 2 weeks of inoculation (19–26). SHIV-KS661c stocks were kept at -80°C and were thawed immediately prior to use.

The animal study design is shown in Fig. 1. Nine cynomolgus monkeys were enrolled and divided into 3 groups, each containing 3 animals. Group 1 was treated with a double dose of FTC/TDF (20/30 mg/kg) 24 h and a few minutes prior to viral exposure; group 2 was given a single dose of FTC/TDF (20/30 mg/kg) 2 weeks before viral exposure; and group 3 (naïve control group) was not treated with any drug. The study was divided into 2 research reports including the current manuscript and the previously published study (27); group 3 was the same in both papers. The drug was formulated in 3 ml of water and was administered intragastrically via a nasal feeding tube under anesthesia. Administration of the drug was followed by the administration of an additional 3 ml of water to wash out any compound remaining in the tube.

All monkeys were then challenged intra-rectally with 10 times the AID_{50} (50% animal infectious dose) of the highly pathogenic SHIV-KS661c. The general condition of the animals, including appetite, activity, and body weight, was carefully observed. Blood chemistry, complete blood cell counts, absolute CD4 cell counts, and plasma virus RNA copy number were measured frequently for over 12 weeks. Finally, the monkeys were sacrificed for virological analysis and analysis of the CD4 population in lymphoid tissues (LTs).

Plasma viral loads were evaluated using real-time reverse transcriptase polymerase chain reaction (RT-PCR) with a TaqMan probe as reported previously

(19–23). Briefly, viral RNA was extracted from the plasma and purified using the QIAamp Viral RNA Mini Kit (Qiagen, Valencia, Calif., USA). For quantitative analysis, TaqMan technology (Applied Biosystems, Foster City, Calif., USA) was used with primers and probes targeting the SIVmac239 *gag* region. Viral RNA was amplified using a QuantiFast Probe RT-PCR Vial Kit (Qiagen) with TaqMan primers and probes. The fluorescence intensity of the RT-PCR product was monitored quantitatively using an Opticon 2 instrument (formerly MJ Research; Bio-Rad, Hercules, Calif., USA). The plasma viral load, measured in duplicate samples, was assessed using a standard curve prepared using control RNA. To assess the RNA recovery rate, 10^5 copies of SHIV-KS661c were extracted and purified using the same kit in parallel with the experimental samples. The recovered RNA was also amplified in parallel with the RNA recovered from the experimental samples. The limit of detection was approximately 500 RNA copies/ml.

The absolute CD4 cell count in peripheral blood (PB) was measured as described previously (19–23). Briefly, 50 μl of whole blood was incubated with FITC-conjugated monoclonal anti-CD3 (FN18; Biosource, Camarillo, Calif., USA), phycoerythrin-conjugated anti-CD4 (Leu-3a; Becton Dickinson, Franklin Lakes, N.J., USA), or peridinin chlorophyll protein-conjugated anti-CD8 (Leu-2a; Becton Dickinson). After erythrocyte lysis using FACS lysis solution (Becton Dickinson), the cells were analyzed with reference beads (Beckman Coulter, Fullerton, Calif., USA) in a FACSCalibur cytometer (Becton Dickinson) using Cell Quest software (Becton Dickinson). The lymphoid cells used for flow cytometric analysis were prepared from thymus, spleen, and lymph node (LN) tissues obtained at necropsy. The cells were stained with the same 3 antibodies described above, and the CD4 population was measured.

The double administration of FTC/TDF (20/30 mg/kg), approximately 24 h and a few minutes before viral exposure, was protective in 2/3 monkeys (Fig. 2, G1). The 2 monkeys protected showed no evidence of CD4 cell depletion during the course of the experiment. We confirmed that anti-HIV-1 and anti-HIV-2 antibodies were not induced in these 2 monkeys (data not shown) and therefore concluded that the animals were completely protected from infection. The unprotected monkey in the same group showed moderate CD4 cell depletion and a moderate peak and set-point viral load in blood. A single administration of FTC/TDF (20/30 mg/kg) approximately 2 weeks before viral exposure failed to protect all 3 monkeys in group 2 (Fig. 2, G2); however, 1 monkey showed moderate CD4 cell depletion (>100 cells/ μl) and lower peak viremia following an undetectable set-point viremia. In group 3 (naïve control; Fig. 2, G3), 2 monkeys showed CD4 cell depletion and high peak viremia that were accompanied by moderate to high set-point viremia. One of 2 monkeys with severe CD4 cell depletion and high viremia was euthanized due to AIDS. Unexpectedly, 1 monkey in group 3 showed moderate CD4 cell depletion (<300 cells/ μl) and low set-point viremia (10^3 – 10^4 copies/ml). No abnormal findings were observed in any other monkey during the course of the experiment.

After over 12 weeks of observation, all animals were

Fig. 2. Effect of PrEP on CD4 cells and viral load in peripheral blood (PB). Absolute CD4 cell counts (cells/ μ l) and virus RNA copy numbers (copies/ml) are shown for PB and plasma, respectively, over the course of the study. Arrows indicate intra-rectal viral challenges. Dash indicates undetectable levels (< 500 copies/ml) in this system. One naïve control monkey (cross in G3) showing severe CD4 cell depletion and high set-point viremia was euthanized due to AIDS.

sacrificed and the CD4 cell population in LTs was analyzed. Macroscopic findings generally suggested that thymus and LNs were atrophic in monkeys showing severe CD4 lymphocytopenia (< 100 cells/ μ l) at necropsy; however, no atrophic tissues were found in monkeys not presenting with severe CD4 lymphocytopenia.

The CD4 cell population in LTs was analyzed by flow cytometry and expressed as the CD4 cell/CD3 cell ratio (%) (Fig. 3). In group 1, CD4 cells were conserved in the LTs of 2 monkeys ($> 24\%$) but showed moderate depletion in the PB of the third monkey. The total CD4/CD3 ratio in group 1, including PB, was significantly higher ($P < 0.01$) than that of group 3. In group 2, the PB CD4 cells of 1 monkey showed no depletion and were well conserved in LTs ($> 30\%$). Interestingly, 2 monkeys with moderate PB CD4 cell depletion had normal thymus CD4 counts (30% and 31%) despite depletion in spleen and LNs (2–11%). Even though no significant difference was found between groups 2 and 3 ($P > 0.05$), the total number of CD4 cells in group 2 appeared greater than in group 3. In contrast, 2 monkeys in group 3 showed severe CD4 cell depletion in all LTs (0–8%), although the CD4 cell counts of another monkey were conserved in all LTs (15–48%).

In this study, the PrEP efficacy of FTC/TDF was evaluated using a highly pathogenic SHIV in a NHP model of AIDS. The study revealed that the double oral administration of FTC/TDF (20/30 mg/kg), 24 h and a few minutes before viral challenge, completely protect-

ed 2/3 monkeys from infection. Although no significant difference between groups 2 and 3 could be detected, the total number of CD4 cells in group 2 appeared greater than in group 3. Thus, we could not conclude that the single administration of FTC/TDF 2 weeks before virus challenge had no preventive effect. The median intracellular half-life of TDF was estimated to be approximately 150 to 180 h, and TDF was still detectable in some patients 14 and 28 days after the administration of the last dose (28,29). The long half-life of TDF might account for the results seen in group 2.

Our results raise one question: is the NHP AIDS model used in the study appropriate for PrEP evaluation? Appropriate animal models provide important tools for obtaining insights into disease prevention and treatment. The SHIV-KS661c/cynomolgus monkey model was developed as a NHP AIDS model to evaluate anti-HIV vaccine candidates and anti-HIV microbicides (17–20). The model has been used to evaluate several anti-HIV candidate drugs such as mycobacterium-based vectors, vaccinia-based vectors, DNA-based vectors, adenovirus-based vectors, and monoclonal antibodies (21–23). SHIV-KS661c is a molecular clone virus derived from SHIV-89.6. Although SHIV-KS661c uses both human CXCR4 and human CCR5 as co-receptors, it is predominantly a CXCR4-tropic virus (18). Upon viral infection of monkeys, high-peak viremia, moderate set-point viremia, and severe CD4 cell depletion occur within several weeks (24–26). On the contrary, SHIV_{SF162p3} used by Garcia-Lerma et al. is CCR5-tropic

Fig. 3. Effect of PrEP on lymphoid tissues (LTs). The CD4 cell populations in LTs at necropsy are shown as the CD4 cell/CD3 cell ratio (%). The CD4/CD3 ratios in PB at necropsy are also shown. The total CD4/CD3 ratios assembled from 5 compartments and analyzed using a one-sided Student's *t* test are shown at the bottom. Narrow bars indicate ranges from minimum to maximum. Boxes indicate standard deviation. Bold bars indicate mean values. **P* < 0.01. PBL, peripheral blood lymphocytes; LN, lymph node.

and does not cause such a rapid CD4 cell depletion (10–13). Therefore, we suggest that both SHIV-KS661c and SHIV-89.6 are highly pathogenic SHIVs. CCR5-tropic HIV populations are generally present throughout the entire course of infection and are predominant during the acute and asymptomatic stages (30); however, CXCR4-tropic and dual-tropic populations emerge during the chronic stage or end stage, which are usually characterized by CD4 cell depletion (31). The frequency of this emergence was recently reported to be low (15%) in individuals infected with HIV subtype C but to be relatively high (60–77%) for other HIV subtypes (32). Transmission of CXCR4-tropic HIV has been reported in some cases (33), although the transmission of CCR5-tropic HIV is the most prominent. Furthermore, there are concerns that the incidence of CXCR4-tropic HIV has increased in several countries (34,35). The introduction and distribution of CCR5 antagonists for HIV treatment may help the emergence of CXCR4-tropic HIV (36–38). These findings support the

idea that blocking both CCR5 and CXCR4 is needed to prevent HIV transmission. Thus, the SHIV-KS661c/cynomolgus monkey is a suitable model for the evaluation of PrEP, particularly because of its CXCR4 tropism.

In this study, single high-dose intrarectal (IR) viral challenge was chosen, although multiple low-dose intravaginal (IVAG) viral challenges would be more representative of HIV infection. A study design involving multiple low-dose viral challenges would have required a larger number of animals per group compared to a study design involving single high-dose inoculations. The majority of HIV infections occur through the vagina, while some are acquired via the rectum or orally. Therefore, IVAG challenge may be a more suitable study design than IR challenge; however, IVAG infectivity depends upon the menstruation cycle (39–41). Regulation of the menstrual cycle so that all study subjects menstruate at the same time is difficult to achieve. Moreover, the narrower and smaller vaginal cavity of cynomolgus monkeys compared to that of rhesus monkeys made it difficult to choose IVAG inoculation. For these reasons, a single high-dose IR challenge was chosen in the present study.

Clinical practice with anti-retroviral therapy clearly suggests that a single drug is not enough to control HIV replication. Recently, Karim et al. reported that a single drug such as TDF gel succeeded in protecting women from vaginal HIV infection (13,42). This is very encouraging; however, the PrEP efficacy of the TDF gel is not very high. A combination of anti-HIV drugs should be used for PrEP and called highly active anti-retroviral prevention or PrEP plus anti-retroviral therapy. Recent mathematical modeling suggested the latter would lower circulating HIV drug resistance (43).

In conclusion, this is the first report demonstrating that FTC/TDF prevents infection with a highly pathogenic and CXCR4-tropic SHIV in a preclinical monkey experimental model. These results support the recent clinical PrEP efficacy of FTC/TDF.

Acknowledgments We would like to thank Dr. W. Heneine from the CDC, Atlanta, USA, and Dr. Y. Tanaka from the University of Ryukyus, Okinawa, Japan, for helpful discussion. We are also grateful to Drs. F. Ono and Y. Katagai for performing necropsies and to Drs. A. Hiyaoka and K. Komatsuzaki from the Corporation for Production and Research of Laboratory Primates, Tsukuba, Japan, for animal care and sampling.

Conflict of interest None to declare.

REFERENCES

1. The Joint United Nations Programme on HIV/AIDS (UNAIDS): INAIDS Report on the Global AIDS Epidemic 2010. Online at <<http://www.unaids.org/globalreport/default.htm>>.
2. Editorial, The Lancet (2007): STEP study: disappointing, but not a failure. *Lancet*, 370, 1665.
3. Steinbrook, R. (2007): One step forward, two steps back—will there ever be an AIDS vaccine? *N. Engl. J. Med.*, 357, 2653–2655.
4. Moore, J.-P., Klasse, P.-J., Dolan, M.-J., et al. (2008): AIDS/HIV. A STEP into darkness or light? *Science*, 320, 753–755.
5. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., et al. (2009): MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV infection in Thailand. *N. Engl. J. Med.*, 361, 2209–2220.

6. Grant, R.-M., Buchbinder, S., Cates, W., Jr., et al. (2005): AIDS. Promote HIV chemoprophylaxis research, don't prevent it. *Science*, 309, 2170–2171.
7. Derdelinckx, I., Wainberg, M.-A., Lange, J.-M., et al. (2006): Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. *PLoS Med.*, 3, e454.
8. Cohen, M.-S., Gay, C., Kashuba, A.-D., et al. (2007): Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV. *Ann. Intern. Med.*, 146, 591–601.
9. Vissers, D.-C., Voeten, H.-A., Nagelkerke, N.-J., et al. (2008): The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. *PLoS One*, 3, e2077.
10. Garcia-Lerma, J.-G., Otten, R.-A., Qari, S.-H., et al. (2008): Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. *PLoS Med.*, 5, e28.
11. Garcia-Lerma, J.-G., Cong, M.-E., Mitchell, J., et al. (2010): Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. *Sci. Transl. Med.*, 2, 14ra4.
12. Garcia-Lerma, J.-G., Paxton, L., Kilmarx, P.-H., et al. (2010): Oral pre-exposure prophylaxis for HIV prevention. *Trends Pharmacol. Sci.*, 31, 74–81.
13. Cong, M.-E., Youngpairoj, A.-S., Zheng, Q., et al. (2011): Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada. *J. Virol.*, 85, 7933–7936.
14. Abdool, Karim, Q., Abdool, Karim, S.-S., Frohlich, J.-A., et al. (2010): Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. *Science*, 329, 1168–1174.
15. Grant, R.-M., Lama, J.-R., Anderson, P.-L., et al. (2012): Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N. Engl. J. Med.*, 363, 2587–2599.
16. Celum, C. and Baeten, J.M. (2012): Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. *Curr. Opin. Infect. Dis.*, 25, 51–57.
17. Shinohara, K., Sakai, K., Ando, S., et al. (1999): A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. *J. Gen. Virol.*, 80, 1231–1240.
18. Kaizu, M., Ami, Y., Nakasone, T., et al. (2003): Higher levels of IL-18 circulate during primary infection of monkeys with a pathogenic SHIV than with a nonpathogenic SHIV. *Virology*, 313, 8–12.
19. Nakasone, T., Sakai, K., Ami, Y., et al. (2002): Genetic and biological characterization of a highly pathogenic molecular clone, SHIV-C2/1 KS661. *J. Med. Primatol.*, 31, 277.
20. Nakasone, T., Kanekiyo, M., Yoshino, N., et al. (2007): Cell-associated SHIV infection in cynomolgus monkeys. *J. Med. Primatol.*, 36, 308–309.
21. Ami, Y., Izumi, Y., Matsuo, K., et al. (2005): Priming-boosting vaccination with recombinant *Mycobacterium bovis* bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. *J. Virol.*, 79, 12871–12879.
22. Murakami, T., Eda, Y., Nakasone, T., et al. (2009): Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4⁺ T-cell loss in macaque lymphoid tissue. *AIDS*, 23, 1485–1494.
23. Someya, K., Xin, K.-Q., Ami, Y., et al. (2007): Chimeric adenovirus type 5/35 vector encoding SIV *gag* and HIV *env* genes affords protective immunity against the simian/human immunodeficiency virus in monkeys. *Virology*, 367, 390–397.
24. Motohara, M., Ibuki, K., Miyake, A., et al. (2006): Impaired T-cell differentiation in the thymus at the early stages of acute pathogenic chimeric simian-human immunodeficiency virus (SHIV) infection in contrast to less pathogenic SHIV infection. *Microbes Infect.*, 8, 1539–1549.
25. Miyake, A., Ibuki, K., Enose, Y., et al. (2006): Rapid dissemination of a pathogenic simian/human immunodeficiency virus to systemic organs and active replication in lymphoid tissues following intrarectal infection. *J. Gen. Virol.*, 87, 1311–1320.
26. Matsuda, K., Inaba, K., Fukazawa, Y., et al. (2010): In vivo analysis of a new R5 tropic SHIV generated from the highly pathogenic SHIV-KS661, a derivative of SHIV-89.6. *Virology*, 399, 134–143.
27. Nakasone, T., Kumakura, S., Yamamoto, M., et al. (2012): Single oral administration of the novel CXCR4 antagonist, KRH-3955, induces an efficient and long-lasting increase of white blood cell count in normal macaques, and prevents CD4 depletion in SHIV-infected macaques: a preliminary study. *Med. Microbiol. Immunol.* doi:10.1007/s00430-012-0254-1
28. Pruvost, A., Negro, E., Benech, H., et al. (2005): Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. *Antimicrob. Agents Chemother.*, 49, 1907–1914.
29. Hawkins, T., Veikley, W., Claire, R.-L., 3rd, et al. (2005): Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. *J. Acquired Immune Defic. Syndr.*, 39, 406–411.
30. Connor, R.-I., Sheridan, K.-E., Ceradini, D., et al. (1997): Change in coreceptor use correlates with disease progression in HIV-infected individuals. *J. Exp. Med.*, 185, 621–628.
31. Xiao, L., Rudolph, D.-L., Owen, S.-M., et al. (1998): Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV disease progression. *AIDS*, 12, F137–143.
32. Esbjörnsson, J., Månsson, F., Martínez-Arias, W., et al. (2010): Frequent CXCR4 tropism of HIV subtype A and CRF02_AG during late-stage disease—indication of an evolving epidemic in West Africa. *Retrovirology*, 7, 23.
33. Huang, W., Eshleman, S.-H., Toma, J., et al. (2009): Vertical transmission of X4-tropic and dual-tropic HIV in five Ugandan mother-infant pairs. *AIDS*, 23, 1903–1908.
34. Raymond, S., Delobel, P., Mavignier, M., et al. (2010): Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. *J. Acquired Immune Defic. Syndr.*, 53, 167–175.
35. Archer, J., Braverman, M.-S., Taillon, B.-E., et al. (2009): Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV with ultra-deep pyrosequencing. *AIDS*, 23, 1209–1218.
36. Tsibris, A.-M., Korber, B., Arnaout, R., et al. (2009): Quantitative deep sequencing reveals dynamic HIV escape and large population shifts during CCR5 antagonist therapy in vivo. *PLoS One*, 4, e5683.
37. Tsibris, A.-M., Sagar, M., Gulick, R.-M., et al. (2008): In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. *J. Virol.*, 82, 8210–8214.
38. Westby, M., Lewis, M., Whitcomb, J., et al. (2006): Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV) variants in a minority of HIV-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. *J. Virol.*, 80, 4909–4920.
39. Marx, P.-A., Spira, A.-I., Gettie, A., et al. (1996): Progesterone implants enhance SIV vaginal transmission and early virus load. *Nat. Med.*, 2, 1084–1089.
40. Sadora, D.-L., Gettie, A., Miller, C.-J., et al. (1998): Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. *AIDS Res. Hum. Retroviruses (Suppl 1)*, S119–123.
41. Smith, S.-M., Baskin, G.-B. and Marx, P.-A. (2000): Estrogen protects against vaginal transmission of simian immunodeficiency virus. *J. Infect. Dis.*, 182, 708–715.
42. Karim, S.-S. (2010): Results of effectiveness trials of PRO 2000 gel: lessons for future microbicide trials. *Future Microbiol.*, 5, 527–529.
43. Supervie, V., Barrett, M., Kahn, J.-S., et al. (2011): Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance. *Sci. Rep.*, 185, Epub 7 Dec 2011.